Benign Prostatic Hyperplasia Treatment Market- Global Industry Analysis and Forecast (2022-2029)


Benign Prostatic Hyperplasia Treatment Market is expected to reach US$ 8.56 Bn. at a CAGR of 5.21% during the forecast period 2029.

Benign Prostatic Hyperplasia Treatment Market

To know about the Research Methodology :- Request Free Sample Report

Benign Prostatic Hyperplasia Treatment Market Overview:

Benign Prostatic Hyperplasia (BHP) is a medical condition, in which the prostate gland gets enlarged and commonly diagnosed in males. It is basically the non-cancerous growth of the gland developed from the prostate cell. The most common indications of these conditions are difficulties in initiating urine, frequent urination, and a weak urinary system.

Benign Prostatic Hyperplasia Treatment Market Dynamics:

Adaptation of unhealthy lifestyle is the key driver contributing to the market growth.

Other factors like the growing population of elderly men and family history encourage the market growth. About one-third of men experience moderate to severe symptoms by age 60, and about half do so by age 80 and heredity causes an increase in the risk of contracting BPH. As many as 14 million men in the United States have symptoms of BPH.

Worldwide, approximately 30 million men have symptoms related to BPH. Studies show that diabetes, as well as heart disease and the use of beta-blockers, might increase the risk of BPH, which in turn raises demand for the BPH treatment market. In addition, the growing health awareness and early diagnosis of the medical condition fuelling the demand for the treatment and propel the market growth. Along with this, the rising preference for minimally invasive surgeries, increasing obesity rate, and investments, funds, and grants for research in the field of BPH treatment stimulate the growth of the BPH treatment market.

However, the high price involving the benign prostatic hyperplasia treatment, expected to hamper the market growth. In addition to this, side effects associated with the BPH medications like dizziness, orthostatic hypotension, retrograde ejaculation, and rhinitis and apart from these some drugs also reduce the synthesis of several neuro-active steroids may impact negatively on the market growth.

The patent expiration of many products has paved the way for a new promising product pipeline high potential in untapped markets of the emerging economies is anticipated to provide lucrative growth opportunities for the market growth during the forecast years.

The report has profiled twenty-nine key players in the market from different regions. However, the report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for a future hot spot in APAC region.

Benign Prostatic Hyperplasia Treatment Market Segment Analysis:

The global Benign Prostatic Hyperplasia Treatment market is segmented on the basis of Drug Type, Surgery Type and End-Users.

Based on Drug Type, the alpha-blockers segment is expected to hold a prominent market share over the forecast years. Alpha-blockers help in relaxing the muscle of the prostate and the bladder neck, which allow urine to flow easier. Alpha-blockers — which include alfuzosin (Uroxatral), doxazosin (Cardura), tamsulosin (Flomax) and silodosin (Rapaflo) — usually work quickly in men with relatively small prostates. In Japan, α1 blockers are recommended in the clinical guidelines for BPH as first-line drug therapy for lower urinary tract symptoms (LUTS) associated with BPH.

Nymox Pharmaceutical Corporation has developed NX-1207 (fexapotide triflutate), a novel compound that is administered transrectally. In July 2015, Nymox announced that its Phase III clinical study of NX-1207 had successfully met its primary endpoints. This injection lasts for a mean duration of 3.5 years after a single injection. The NX-1207 is considered to be safe as compared to existing treatments with minimal side effects.

Based on Surgery Type, the TURP (Transurethral resection of the prostate) segment is considered to be dominant over the forecast years. TURP is an endoscopic electrosurgical procedure involving the removal of a portion of the prostate to relieve voiding obstruction associated with BPH. A lighted scope is inserted into your urethra, and the surgeon removes all but the outer part of the prostate.

Owing to the growing trend, nowadays, TURP is being performed on an outpatient basis and selected patients are granted discharge within 24 hours of admission. Advantages associated with TURP such as less hospital stay and quick recovery encourage the segment to grow at a faster pace during the forecast period.

Benign Prostatic Hyperplasia Treatment Market Regional Insights:

North America region is anticipated to hold the largest market share.

The high prevalence of BPH and other associated lower urinary tract symptoms present in the region is the major factor dominating the market in North America. Several studies in the past era have reported a significant percentage of men in the US, aged between 45 and 80 years suffer from some type of lower urinary tract symptoms and most have some form of BPH symptoms.

Collaboration of many hospitals with non-profit organization and companies in the US and Canada, contribute to raising awareness and adequate resources for the treatment of urological disorders. The American Medical Systems portfolio acquisition included the procurement of leading products for the treatment of a variety of urologic conditions, including the minimally invasive GreenLight XPS laser therapy system.

Asia-Pacific region is anticipated to grow at a faster pace during the forecast period, owing to a high population base, increase in disposable income, and enhanced patient awareness about the benign prostatic hyperplasia condition.

The report also helps in understanding the Global Benign Prostatic Hyperplasia Treatment Market dynamics, structure by analyzing the market segments and project the Global Benign Prostatic Hyperplasia Treatment Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Benign Prostatic Hyperplasia Treatment Market make the report investor’s guide.

Benign Prostatic Hyperplasia Treatment Market Key Developments:

• In August 2015, Boston Scientific completed its acquisition of American Medical Systems’ Male Urology Portfolio from Endo Pharmaceuticals for $1.6bn, with the potential for an additional $50m in milestone payments predicated on 2016 sales. As a result of this acquisition, Boston Scientific positioned itself as the market leader in laser-based surgery systems and an overall leader in urology with its comprehensive portfolio. The new business portfolio was combined with Boston Scientific’s Urology and Women’s Health businesses to create the new Urology and Pelvic Health business.

• The new handheld Rezūm device manufactured by NxThera, performs Prostate Convective WAVE ablation. This innovation is considered as a source of growth in the market for office-based thermotherapy for symptomatic BPH. The Rezūm device is expected to see an increase in sales over the forecast period.

Benign Prostatic Hyperplasia Treatment Market Scope: Inquire before buying






Benign Prostatic Hyperplasia Treatment Market




Report Coverage
Details




Base Year:
2021
Forecast Period:
2022-2029




Historical Data:
2017 to 2021
Market Size in 2021:
US $ 5.7 Bn.




Forecast Period 2022 to 2029 CAGR:
5.21%
Market Size in 2029:
US $ 8.56 Bn.




 Segments Covered:
by Product
• Alpha-Blockers
• 5- Alpha-Reductase Inhibitors (5-Aris)
• Alpha-Adrenergic Blockers
• Phosphodiesterase-5 Enzyme Inhibitors
• Other Drug Types




by Type
• TURP
• TUMT
• TUNA




by Application
• Home healthcare
• Hospitals & clinics






Benign Prostatic Hyperplasia Treatment Market, by Region

• North America
• Europe
• South America
• MEA
• APAC

Benign Prostatic Hyperplasia Treatment Market Key Players

• Boston Scientific Corporation
• Coloplast Group
• Teleflex Incorporated
• Olympus Corporation
• GlaxoSmithKline PLC
• Eli Lilly
• Pfizer, Inc.
• Abbott
• Asahi Kasei Corporation
• Merck & Co., Inc.
• Astellas Pharma Inc.
• Allergan plc
• Alembic
• IPG Photonics Corporation
• Richard Wolf GmbH
• Unilab, Inc.
• Pharex Health Corporation
• Biolitec AG
• Urologix, LLC
• Advin Health Care
• Medifocus, Inc.
• Asclepion Laser Technologies GmbH
• Pnn Medical A/S
• Surgical Lasers Inc.
• Quanta Systems
• Allium Ltd.
• Lumenis Ltd.
• KARL STORZ SE & Co. KG
• SRS Medical

Frequently Asked Questions:

1. Which region has the largest share in Global Benign Prostatic Hyperplasia Treatment Market?
Ans: North America region holds the highest share in 2021.

2. What is the growth rate of Global Benign Prostatic Hyperplasia Treatment Market?
Ans: The Global Benign Prostatic Hyperplasia Treatment Market is growing at a CAGR of 5.21%during forecasting period 2022-2029.

3. What is scope of the Global Benign Prostatic Hyperplasia Treatment market report?
Ans: Global Benign Prostatic Hyperplasia Treatment Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Benign Prostatic Hyperplasia Treatment market?
Ans: The important key players in the Global Benign Prostatic Hyperplasia Treatment Market are – Boston Scientific Corporation, Coloplast Group, Teleflex Incorporated, Olympus Corporation, GlaxoSmithKline PLC, Eli Lilly, Pfizer, Inc., Abbott, Asahi Kasei Corporation, Merck & Co., Inc., Astellas Pharma Inc., Allergan plc, Alembic, IPG Photonics Corporation, Richard Wolf GmbH, Unilab, Inc., Pharex Health Corporation, Biolitec AG, Urologix, LLC, Advin Health Care, Medifocus, Inc., Asclepion Laser Technologies GmbH, Pnn Medical A/S, Surgical Lasers Inc., Quanta Systems, Allium Ltd., Lumenis Ltd., KARL STORZ SE & Co. KG, and SRS Medical

5. What is the study period of this market?
Ans: The Global Benign Prostatic Hyperplasia Treatment Market is studied from 2021 to 2029. 




1. Preface
1.1. Market Definition and Key Research Objectives
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources
3. Executive Summary: Global Benign Prostatic Hyperplasia Treatment Market Size, by Market Value (US$ Mn)
3.1. Global Market Segmentation
3.2. Global Market Segmentation Share Analysis, 2021
3.2.1. Global
3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa)
3.3. Geographical Snapshot of the Benign Prostatic Hyperplasia Treatment Market
3.4. Geographical Snapshot of the Benign Prostatic Hyperplasia Treatment Market, By Manufacturer share
4. Global Benign Prostatic Hyperplasia Treatment Market Overview, 2021-2029
4.1. Market Dynamics
4.1.1. Drivers
4.1.1.1. Global
4.1.1.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa)
4.1.2. Restraints
4.1.2.1. Global
4.1.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa)
4.1.3. Opportunities
4.1.3.1. Global
4.1.3.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa)
4.1.4. Challenges
4.1.4.1. Global
4.1.4.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa)
4.1.5. Industry Trends and Emerging Technologies
4.1.6. Porters Five Forces Analysis
4.1.6.1. Threat of New Entrants
4.1.6.2. Bargaining Power of Buyers/Consumers
4.1.6.3. Bargaining Power of Suppliers
4.1.6.4. Threat of Substitute Products
4.1.6.5. Intensity of Competitive Rivalry
4.1.7. Value Chain Analysis
4.1.8. Technological Roadmap
4.1.9. Regulatory landscape
4.1.10. Impact of the Covid-19 Pandemic on the Global Benign Prostatic Hyperplasia Treatment Market
5. Supply Side and Demand Side Indicators
6. Global Benign Prostatic Hyperplasia Treatment Market Analysis and Forecast, 2021-2029
6.1. Global Benign Prostatic Hyperplasia Treatment Market Size & Y-o-Y Growth Analysis.
7. Global Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, 2021-2029
7.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029
7.1.1. Alpha-Blockers
7.1.2. 5- Alpha-Reductase Inhibitors (5-Aris)
7.1.3. Alpha-Adrenergic Blockers
7.1.4. Phosphodiesterase-5 Enzyme Inhibitors
7.1.5. Other Drug Types
7.2. Market Size (Value) Estimates & Forecast By Surgery Type , 2021-2029
7.2.1. TURP
7.2.2. TUMT
7.2.3. TUNA
7.3. Market Size (Value) Estimates & Forecast By End-Users, 2021-2029
7.3.1. Home healthcare
7.3.2. Hospitals & clinics
8. Global Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, By Region
8.1. Market Size (Value) Estimates & Forecast By Region, 2021-2029
8.1.1. North America
8.1.2. Europe
8.1.3. Asia-Pacific
8.1.4. Middle East & Africa
8.1.5. South America
9. North America Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, 2021-2029
9.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029
9.1.1. Alpha-Blockers
9.1.2. 5- Alpha-Reductase Inhibitors (5-Aris)
9.1.3. Alpha-Adrenergic Blockers
9.1.4. Phosphodiesterase-5 Enzyme Inhibitors
9.1.5. Other Drug Types
9.2. Market Size (Value) Estimates & Forecast By Surgery Type , 2021-2029
9.2.1. TURP
9.2.2. TUMT
9.2.3. TUNA
9.3. Market Size (Value) Estimates & Forecast By End-Users, 2021-2029
9.3.1. Home healthcare
9.3.2. Hospitals & clinics
10. North America Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, By Country
10.1. Market Size (Value) Estimates & Forecast By Country, 2021-2029
10.1.1. US
10.1.2. Canada
10.1.3. Mexico
11. U.S. Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, 2021-2029
11.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029
11.2. Market Size (Value) Estimates & Forecast By Surgery Type , 2021-2029
11.3. Market Size (Value) Estimates & Forecast By End-Users, 2021-2029
12. Canada Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, 2021-2029
12.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029
12.2. Market Size (Value) Estimates & Forecast By Surgery Type , 2021-2029
12.3. Market Size (Value) Estimates & Forecast By End-Users, 2021-2029
13. Mexico Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, 2021-2029
13.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029
13.2. Market Size (Value) Estimates & Forecast By Surgery Type , 2021-2029
13.3. Market Size (Value) Estimates & Forecast By End-Users, 2021-2029
14. Europe Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, 2021-2029
14.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029
14.2. Market Size (Value) Estimates & Forecast By Surgery Type , 2021-2029
14.3. Market Size (Value) Estimates & Forecast By End-Users, 2021-2029
15. Europe Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, By Country
15.1. Market Size (Value) Estimates & Forecast By Country, 2021-2029
15.1.1. U.K
15.1.2. France
15.1.3. Germany
15.1.4. Italy
15.1.5. Spain
15.1.6. Sweden
15.1.7. CIS Countries
15.1.8. Rest of Europe
16. U.K. Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, 2021-2029
16.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029
16.2. Market Size (Value) Estimates & Forecast By Surgery Type , 2021-2029
16.3. Market Size (Value) Estimates & Forecast By End-Users, 2021-2029
17. France Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, 2021-2029
17.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029
17.2. Market Size (Value) Estimates & Forecast By Surgery Type , 2021-2029
17.3. Market Size (Value) Estimates & Forecast By End-Users, 2021-2029
18. Germany Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, 2021-2029
18.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029
18.2. Market Size (Value) Estimates & Forecast By Surgery Type , 2021-2029
18.3. Market Size (Value) Estimates & Forecast By End-Users, 2021-2029
19. Italy Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, 2021-2029
19.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029
19.2. Market Size (Value) Estimates & Forecast By Surgery Type , 2021-2029
19.3. Market Size (Value) Estimates & Forecast By End-Users, 2021-2029
20. Spain Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, 2021-2029
20.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029
20.2. Market Size (Value) Estimates & Forecast By Surgery Type , 2021-2029
20.3. Market Size (Value) Estimates & Forecast By End-Users, 2021-2029
21. Sweden Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, 2021-2029
21.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029
21.2. Market Size (Value) Estimates & Forecast By Surgery Type , 2021-2029
21.3. Market Size (Value) Estimates & Forecast By End-Users, 2021-2029
22. CIS Countries Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, 2021-2029
22.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029
22.2. Market Size (Value) Estimates & Forecast By Surgery Type , 2021-2029
22.3. Market Size (Value) Estimates & Forecast By End-Users, 2021-2029
23. Rest of Europe Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, 2021-2029
23.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029
23.2. Market Size (Value) Estimates & Forecast By Surgery Type , 2021-2029
23.3. Market Size (Value) Estimates & Forecast By End-Users, 2021-2029
24. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, 2021-2029
24.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029
24.2. Market Size (Value) Estimates & Forecast By Surgery Type , 2021-2029
24.3. Market Size (Value) Estimates & Forecast By End-Users, 2021-2029
25. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, by Country
25.1. Market Size (Value) Estimates & Forecast By Country, 2021-2029
25.1.1. China
25.1.2. India
25.1.3. Japan
25.1.4. South Korea
25.1.5. Australia
25.1.6. ASEAN
25.1.7. Rest of Asia Pacific
26. China Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, 2021-2029
26.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029
26.2. Market Size (Value) Estimates & Forecast By Surgery Type , 2021-2029
26.3. Market Size (Value) Estimates & Forecast By End-Users, 2021-2029
27. India Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, 2021-2029
27.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029
27.2. Market Size (Value) Estimates & Forecast By Surgery Type , 2021-2029
27.3. Market Size (Value) Estimates & Forecast By End-Users, 2021-2029
28. Japan Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, 2021-2029
28.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029
28.2. Market Size (Value) Estimates & Forecast By Surgery Type , 2021-2029
28.3. Market Size (Value) Estimates & Forecast By End-Users, 2021-2029
29. South Korea Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, 2021-2029
29.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029
29.2. Market Size (Value) Estimates & Forecast By Surgery Type , 2021-2029
29.3. Market Size (Value) Estimates & Forecast By End-Users, 2021-2029
30. Australia Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, 2021-2029
30.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029
30.2. Market Size (Value) Estimates & Forecast By Surgery Type , 2021-2029
30.3. Market Size (Value) Estimates & Forecast By End-Users, 2021-2029
31. ASEAN Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, 2021-2029
31.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029
31.2. Market Size (Value) Estimates & Forecast By Surgery Type , 2021-2029
31.3. Market Size (Value) Estimates & Forecast By End-Users, 2021-2029
32. Rest of Asia Pacific Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, 2021-2029
32.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029
32.2. Market Size (Value) Estimates & Forecast By Surgery Type , 2021-2029
32.3. Market Size (Value) Estimates & Forecast By End-Users, 2021-2029
33. Middle East Africa Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, 2021-2029
33.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029
33.2. Market Size (Value) Estimates & Forecast By Surgery Type , 2021-2029
33.3. Market Size (Value) Estimates & Forecast By End-Users, 2021-2029
34. Middle East Africa Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, by Country
34.1. Market Size (Value) Estimates & Forecast by Country, 2021-2029
34.1.1. South Africa
34.1.2. GCC Countries
34.1.3. Egypt
34.1.4. Nigeria
34.1.5. Rest of ME&A
35. South Africa Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, 2021-2029
35.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029
35.2. Market Size (Value) Estimates & Forecast By Surgery Type , 2021-2029
35.3. Market Size (Value) Estimates & Forecast By End-Users, 2021-2029
36. GCC Countries Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, 2021-2029
36.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029
36.2. Market Size (Value) Estimates & Forecast By Surgery Type , 2021-2029
36.3. Market Size (Value) Estimates & Forecast By End-Users, 2021-2029
37. Egypt Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, 2021-2029
37.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029
37.2. Market Size (Value) Estimates & Forecast By Surgery Type , 2021-2029
37.3. Market Size (Value) Estimates & Forecast By End-Users, 2021-2029
38. Nigeria Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, 2021-2029
38.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029
38.2. Market Size (Value) Estimates & Forecast By Surgery Type , 2021-2029
38.3. Market Size (Value) Estimates & Forecast By End-Users, 2021-2029
39. Rest of ME&A Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, 2021-2029
39.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029
39.2. Market Size (Value) Estimates & Forecast By Surgery Type , 2021-2029
39.3. Market Size (Value) Estimates & Forecast By End-Users, 2021-2029
40. South America Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, 2021-2029
40.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029
40.2. Market Size (Value) Estimates & Forecast By Surgery Type , 2021-2029
40.3. Market Size (Value) Estimates & Forecast By End-Users, 2021-2029
41. South America Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, by Country
41.1. Market Size (Value) Estimates & Forecast by Country, 2021-2029
41.1.1. Brazil
41.1.2. Argentina
41.1.3. Rest of South America
42. Brazil Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, 2021-2029
42.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029
42.2. Market Size (Value) Estimates & Forecast By Surgery Type , 2021-2029
42.3. Market Size (Value) Estimates & Forecast By End-Users, 2021-2029
43. Argentina Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, 2021-2029
43.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029
43.2. Market Size (Value) Estimates & Forecast By Surgery Type , 2021-2029
43.3. Market Size (Value) Estimates & Forecast By End-Users, 2021-2029
44. Rest of South America Benign Prostatic Hyperplasia Treatment Market Analysis and Forecasts, 2021-2029
44.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029
44.2. Market Size (Value) Estimates & Forecast By Surgery Type , 2021-2029
44.3. Market Size (Value) Estimates & Forecast By End-Users, 2021-2029
45. Competitive Landscape
45.1. Geographic Footprint of Major Players in the Global Benign Prostatic Hyperplasia Treatment Market
45.2. Competition Matrix
45.2.1. Competitive Benchmarking of Key Players By Price, Presence, Market Share, Applications and R&D Investment
45.2.2. New Product Launches and Product Enhancements
45.2.3. Market Consolidation
45.2.3.1. M&A by Regions, Investment and Verticals
45.2.3.2. M&A, Forward Integration and Backward
Integration
45.2.3.3. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
45.3. Company Profile : Key Players
45.3.1. Boston Scientific Corporation
45.3.1.1. Company Overview
45.3.1.2. Financial Overview
45.3.1.3. Geographic Footprint
45.3.1.4. Product Portfolio
45.3.1.5. Business Strategy
45.3.1.6. Recent Developments
45.3.2. Coloplast Group
45.3.3. Teleflex Incorporated
45.3.4. Olympus Corporation
45.3.5. GlaxoSmithKline PLC
45.3.6. Eli Lilly
45.3.7. Pfizer, Inc.
45.3.8. Abbott
45.3.9. Asahi Kasei Corporation
45.3.10. Merck & Co., Inc.
45.3.11. Astellas Pharma Inc.
45.3.12. Allergan plc
45.3.13. Alembic
45.3.14. IPG Photonics Corporation
45.3.15. Richard Wolf GmbH
45.3.16. Unilab, Inc.
45.3.17. Pharex Health Corporation
45.3.18. Biolitec AG
45.3.19. Urologix, LLC
45.3.20. Advin Health Care
45.3.21. Medifocus, Inc.
45.3.22. Asclepion Laser Technologies GmbH
45.3.23. Pnn Medical A/S
45.3.24. Surgical Lasers Inc.
45.3.25. Quanta Systems
45.3.26. Allium Ltd.
45.3.27. Lumenis Ltd.
45.3.28. KARL STORZ SE & Co. KG
45.3.29. SRS Medical
46. Primary Key Insights
  • INQUIRE BEFORE BUYING